Docosahexaenoic Acid Targets TRPC3/6 Channels to Suppress Noradrenaline-Induced Contraction in Rat Vas Deferens Smooth Muscle
We investigated the effects of docosahexaenoic acid (DHA) on noradrenaline (NA)-induced contractile responses in rat vas deferens smooth muscle (VDSM). DHA (3 × 10<sup>-6</sup>-3 × 10<sup>-5</sup> M) significantly inhibited phasic contractions induced by NA (3 × 10<sup>-5</sup> M) in a concentration-dependent manner. In contrast, under Ca<sup>2+</sup>-free conditions, DHA (3 × 10<sup>-5</sup> M) slightly enhanced NA-induced contractile responses. DHA did not inhibit NA-induced contractile responses in the prostate, which are mediated by α<sub>1A</sub>-adrenoceptor stimulation, similar to those in VDSM. Although verapamil (10<sup>-5</sup> M), an L-type Ca<sup>2+</sup> channel inhibitor, partially suppressed NA-induced contractile responses in VDSM, a substantial phasic component persisted. The residual phasic component was unaffected by LOE-908 (a receptor-operated Ca<sup>2+</sup> channel inhibitor, 3 × 10<sup>-5</sup> M), but was markedly inhibited by SKF-96365 (an inhibitor of both receptor-operated and store-operated Ca<sup>2+</sup> channels, 3 × 10<sup>-5</sup> M). Among inhibitors targeting store-operated Ca<sup>2+</sup> channel candidates with high mRNA expression in VDSM, GSK417651A (10<sup>-5</sup> M) and Pyr10 (3 × 10<sup>-5</sup> M)-both putative inhibitors of transient receptor potential canonical 3/6 (TRPC3/6) channels-effectively inhibited the contractile response, whereas inhibitors targeting Orai1, transient receptor potential vanilloid 4 (TRPV4), or TRPC1/4/5 did not exert inhibitory effects. Similarly, under combined treatment with verapamil and LOE-908, contractile responses induced by cyclopiazonic acid (3 × 10<sup>-5</sup> M, a sarco/endoplasmic reticulum Ca<sup>2+</sup>-ATPase inhibitor) were reduced by DHA, SKF-96365, and putative TRPC3/6 inhibitors, but not by inhibitors of Orai1, TRPV4, or TRPC1/4/5. These findings indicate that DHA suppresses NA-induced contractile responses in VDSM, primarily through inhibition of TRPC3/6 channels.
Authors
- Masakazu Enomoto
- Yoshio Tanaka (ORCID: https://orcid.org/0000-0002-8341-3809)
- Kento Yoshioka (ORCID: https://orcid.org/0000-0003-1701-3759)
- Keisuke Takahashi (ORCID: https://orcid.org/0000-0002-1438-9091)
- Takeshi Ura
- Keisuke Obara (ORCID: https://orcid.org/0000-0001-9226-4086)
- Keisuke Kato (ORCID: https://orcid.org/0000-0003-4408-4181)
- Taichi Kusakabe
- Hiyori Nasu
- M. Furuta
- Hiroyuki Okura
- Ayu Kato
- T Mouri
- Minori Gohara
Institutions
- Toho University (JP)
Publication Details
- Journal
- Biological and Pharmaceutical Bulletin
- Published
- 2025-09-29
- DOI
- https://doi.org/10.1248/bpb.b25-00428
- Primary Topic
- Coenzyme Q10 studies and effects
- Type
- article
- Field-Weighted Citation Impact
- 0.00